LENZ Therapeutics, Inc. LENZ
NASDAQ · United States · Health Technology
$3.79-0.05 (-1.30%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83 per share, which now lines up more closely with the US$7 price target cluster that many firms reference. This reset reflects the more cautious stance in recent research, where several analysts cut price targets and moved to Neutral while they reassess the VIZZ launch and the company’s cash support. As you read on, you will see how these moving targets shape the evolving LENZ Therapeutics...
Strong cash position and expanding global partnerships offset modest Q2 product revenue growth as the company scales commercial execution.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.